RxDoctor Payments Data

David Ozog, MD

MOHS-Micrographic Surgery · Detroit, MINPI 1083792113

Payments from drug & device makers

What this record shows

This record is dominated by grants: $21,428 of the $21,967 with a category attached, or 97.5%. Galderma Laboratories, L.p. accounts for 99.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $14,267 and has fallen 98.9% since, to $155 in 2025. Among mohs-micrographic surgery clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,967in general payments, 2019–2025

Across 12 payments — averaging $1830.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$22K
  • AbbVie$176
  • Novartis$50
$253,833in research payments, 2019–2025

Across 13 payments — averaging $19,526 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biofrontera Inc.$244K
  • Biofrontera Bioscience GmbH$10K

What the payments were for

  • Grants$21,42898%
  • Food & beverage$5382%

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Galderma Laboratories, L.p.7$21,740
AbbVie4$176
Novartis1$50

How this compares

$21,967 in reported general payments places this provider in the 95th percentile of 30 mohs-micrographic surgery providers in Michigan.

See all mohs-micrographic surgery providers in Michigan

Medicare billing

Part B allowed, 2024
$55,590
Medicare patients
107
Services billed
315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin41$142

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →